BioWorld MedTech

June 3, 2016

View Archived Issues

China Resources exits med-tech space to focus on other health care areas

FDA clarifies how IDE categories work as they relate to Medicare coverage

Financings

Appointments & Advancements

Other news to note

Product briefs

Keeping you up to date on recent developments with diagnostics

FDA approves first liquid biopsy test to aid clinical decisions based on EGFR mutation

Roche Holding AG, of Basel, Switzerland, is the first company with an FDA-approved, blood-based genetic test to detect a gene mutation associated with the most common type of lung cancer. Read More

France's AAA gets FDA win for Netspot to locate rare tumors

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...